• A combined immunopeptidomics, proteomics, and cell surface proteomics approach to identify immunotherapy targets for diffuse intrinsic pontine glioma
• A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4
• A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor
• A Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium (PBTC-047)
• A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered
• ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma
• Adaptive rewiring of purine metabolism promotes treatment resistance in H3K27M-mutant diffuse midline glioma
• Addressing barriers in diffuse intrinsic pontine glioma: the transformative role of lipid nanoparticulate drug delivery
• Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium
• An Update on H3K27M-altered Diffuse Midline Glioma: Diagnostic and Therapeutic Challenges in Clinical Practice
• B7-H3 in Brain Malignancies: Immunology and Immunotherapy
• Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies
• Bevacizumab for the early clinical progression of diffuse intrinsic pontine glioma
• BMP signaling in cancer stemness and differentiation
• Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?
• Boswellic acid formulations are not suitable for treatment of pediatric high-grade glioma due to tumor promoting potential
• Bridging the age gap: a review of molecularly informed treatments for glioma in adolescents and young adults
• CAR T cell therapies for diffuse midline glioma
• CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas
• Case Report: Low-grade glioma with NF1 loss of function mimicking diffuse intrinsic pontine glioma
• Central nervous system regulation of diffuse glioma growth and invasion: from single unit physiology to circuit remodeling
• Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201
• Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location
• Classification of Brainstem Gliomas Based on Tumor Microenvironment Status
• Clinical characteristics and prognostic factors of surgical treatment in children with brainstem tumor
• Clinical experience with immunotherapy in patients with diffuse intrinsic pontine glioma
• Contemporary Management of Pediatric Brainstem Tumors
• Correction to: The relationship between imaging features, therapeutic response, and overall survival in pediatric diffuse intrinsic pontine glioma
• Current immunotherapeutic approaches to diffuse intrinsic pontine glioma
• Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma
• Detection of cell-free histones in the cerebrospinal fluid of pediatric central nervous system malignancies by imaging flow cytometry
• Diffuse Intrinsic Pontine Glioma
• Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies
• Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon
• Diffuse Midline Gliomas: Challenges and New Strategies in a Changing Clinical Landscape
• Dimethyl alpha-ketoglutarate inhibits proliferation in diffuse intrinsic pontine glioma by reprogramming epigenetic and transcriptional networks
• Discovery of Conformationally Constrained ALK2 Inhibitors
• DNA methylation landscapes in DIPG reveal methylome variability that can be modified pharmacologically
• DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines
• Effects of tumour heterogeneous properties on modelling the transport of radiative particles
• Efficacy and safety of hypofractionated radiotherapy versus conventional fractionated radiotherapy in diffuse intrinsic pontine glioma: A systematic review and meta-analysis
• Emerging strategies to fabricate polymeric nanocarriers for enhanced drug delivery across blood-brain barrier: An overview
• Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma
• Evaluating drug distribution in children and young adults with diffuse midline glioma of the pons (DIPG) treated with convection-enhanced drug delivery
• Expression of Interleukin-13 Receptor Alpha 2 in Brainstem Gliomas
• Extra-neural metastases in pediatric diffuse midline gliomas, H3 K27-altered: presentation of two cases and literature review
• Fifty years of DIPG: looking at the future with hope
• Fimepinostat Impairs NF-kappaB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma
• Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma
• Fimepinostat impairs NF-κB and PI3K/AKT signaling and enhances gemcitabine efficacy in H3K27M-mutated diffuse intrinsic pontine glioma
• Fragment-based discovery of small molecule inhibitors of the HDGFRP2 PWWP domain
• From Pediatric to Adult Brain Cancer: Exploring Histone H3 Mutations in Australian Brain Cancer Patients
• Glioma synapses recruit mechanisms of adaptive plasticity
• H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells
• H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions
• H3(K27)-Altered Diffuse Glioma of the Spinal Cord in Adult Patients: A Qualitative Systematic Review and Peculiarity of Radiological Findings
• Harmaline to Human Mitochondrial Caseinolytic Serine Protease Activation for Pediatric Diffuse Intrinsic Pontine Glioma Treatment
• Helical tomotherapy craniospinal irradiation in primary brain tumours: Toxicities and outcomes in a peadiatric and adult population
• High Level Immunoglobulin Gene Expression and Reduced Intra-tumoral Bacteria Associated With the Transition from Initial to Progressive Diffuse Intrinsic Pontine Glioma
• Hypofractionated re-irradiation for diffuse intrinsic pontine glioma
• Imaging biomarkers and radiomics in pediatric oncology: a view from the PRIMAGE (PRedictive In silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers) project
• Implementing data on targeted therapy from the INFORM registry platform for children with relapsed cancer in Sweden
• In vitro vascular differentiation system efficiently produces natural killer cells for cancer immunotherapies
• Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase 1 trial
• Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
• Influence of socioeconomic status on clinical outcomes of diffuse midline glioma and diffuse intrinsic pontine glioma
• Just a spoonful of metformin helps the medicine go down
• Laminin-associated integrins mediate Diffuse Intrinsic Pontine Glioma infiltration and therapy response within a neural assembloid model
• Letter to the Editor: "The relationship between imaging features, therapeutic response, and overall survival in pediatric diffuse intrinsic pontine glioma"
• Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children's Haematology/Oncology Group position statement
• Medullary brainstem gliomas in an adult: A rare case report and challenging tumor
• Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas
• MRI-guided focused ultrasound blood-brain barrier opening increases drug delivery and efficacy in a diffuse midline glioma mouse model
• Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma
• Palliative care for children with central nervous system tumors: results of a Spanish multicenter study
• Parsing the effect of co-culture with brain organoids on Diffuse Intrinsic Pontine Glioma (DIPG) using quantitative proteomics
• Pediatric diffuse intrinsic pontine glioma radiotherapy response prediction: MRI morphology and T2 intensity-based quantitative analyses
• Pediatric Diffuse Midline Glioma H3K27-Altered: From Developmental Origins to Therapeutic Challenges
• Pharmacological Targeting of Interferon-Related DNA Damage Resistant Signature (IRDS) and XRCC4-Mediated DNA Repair Pathways ss a Novel Therapeutic Approach to DIPG Radio-Sensitization
• Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)
• PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
• Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma
• Rapid Peroxide Removal Limits the Radiosensitization of Diffuse Intrinsic Pontine Glioma (DIPG) Cells by Pharmacologic Ascorbate
• Re-Irradiation for Diffuse Intrinsic Pontine Glioma with 3 Gy per Fraction
• Reirradiation for diffuse intrinsic pontine glioma: prognostic radiomic factors at progression
• Review of imaging recommendations from Response Assessment in Pediatric Neuro-Oncology (RAPNO)
• Safety and Efficacy of Biopsy in Patients with Diffuse Intrinsic Pontine Gliomas
• Spontaneous Regression of Glioma-Mimicking Brainstem Lesion in a Child: A Case Report
• Survival and neurological outcomes after stereotactic biopsy of diffuse intrinsic pontine glioma: a systematic review
• Targeting diffuse midline gliomas: The promise of focused ultrasound-mediated blood-brain barrier opening
• Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence
• The relationship between imaging features, therapeutic response, and overall survival in pediatric diffuse intrinsic pontine glioma
• The role of focused ultrasound for pediatric brain tumors: current insights and future implications on treatment strategies
• The Role of Reirradiation in Childhood Progressive Diffuse Intrinsic Pontine Glioma (DIPG): An Ongoing Challenge beyond Radiobiology
• Theranostic Intratumoral Convection-Enhanced Delivery of (124)I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry
• Theranostic Uses of the Heme Pathway in Neuro-Oncology: Protoporphyrin IX (PpIX) and Its Journey from Photodynamic Therapy (PDT) through Photodynamic Diagnosis (PDD) to Sonodynamic Therapy (SDT)
• Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma
• TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
• TIM-3 blockade: immune and targeted therapy in DIPG
• Very Long-term Survivorship in Pediatric DIPG: Case Report and Review of the Literature